77 related articles for article (PubMed ID: 16378783)
1. What do patients consider when making decisions about treatment for hepatitis C?
Fraenkel L; McGraw S; Wongcharatrawee S; Garcia-Tsao G
Am J Med; 2005 Dec; 118(12):1387-91. PubMed ID: 16378783
[TBL] [Abstract][Full Text] [Related]
2. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
Rogers CJ; Romagosa R; Vincek V
J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
[No Abstract] [Full Text] [Related]
3. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
[TBL] [Abstract][Full Text] [Related]
4. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
Demirturk N; Aykin N; Demirdal T; Cevik F
Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
[No Abstract] [Full Text] [Related]
5. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
[TBL] [Abstract][Full Text] [Related]
6. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
7. A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C.
Tavakoli-Tabasi S; Bagree A
J Clin Gastroenterol; 2012 Feb; 46(2):162-7. PubMed ID: 21814144
[TBL] [Abstract][Full Text] [Related]
8. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
[No Abstract] [Full Text] [Related]
9. Peginterferon and ribavirin for chronic hepatitis C.
Hoofnagle JH; Seeff LB
N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
[No Abstract] [Full Text] [Related]
10. Thyrotoxic periodic paralysis induced by pegylated interferon alpha plus ribavirin for chronic hepatitis C.
Yang WS; Chu PL; Liu CH; Chung GB; Wu KD
J Clin Gastroenterol; 2008 Jan; 42(1):112-3. PubMed ID: 18097301
[No Abstract] [Full Text] [Related]
11. [Side effects of the combined antiviral therapy in patients with chronic hepatitis C].
Vashakidze ET; Gegeshidze TN; Zhamutashvili MT; Svanidze MB
Georgian Med News; 2007; (148-149):26-8. PubMed ID: 17921538
[TBL] [Abstract][Full Text] [Related]
12. [Antiviral therapy of patients with chronic hepatitis C with normal level of aminotransferases].
Lopukhova NL
Eksp Klin Gastroenterol; 2007; (4):146-52. PubMed ID: 18409502
[No Abstract] [Full Text] [Related]
13. Modifications of haematological series in patients co-infected with human immunodeficiency virus and hepatitis C virus during treatment with interferon and ribavirin: differences between pegylated and standard interferon.
Arizcorreta A; Brun F; Fernández-Gutiérrez C; García Juárez R; Guerrero F; Pérez-Guzmán E; Girón-González JA
Clin Microbiol Infect; 2004 Dec; 10(12):1067-74. PubMed ID: 15606633
[TBL] [Abstract][Full Text] [Related]
14. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
Fontana RJ; Bieliauskas LA; Lindsay KL; Back-Madruga C; Wright EC; Snow KK; Lok AS; Kronfol Z; Padmanabhan L;
Hepatology; 2007 May; 45(5):1154-63. PubMed ID: 17465000
[TBL] [Abstract][Full Text] [Related]
15. [Cutaneous reactions induced by pegylated-interferon plus ribavirin combination therapy in a patient with chronic hepatitis C].
Enjoji M; Dainichi T; Gondo H; Urabe K
Fukuoka Igaku Zasshi; 2007 Sep; 98(9):353-6. PubMed ID: 17974079
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of hepatitis C].
Moradpour D; Blum HE
Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
[TBL] [Abstract][Full Text] [Related]
17. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
[TBL] [Abstract][Full Text] [Related]
18. Therapy of hepatitis C: from empiricism to eradication.
Pawlotsky JM
Hepatology; 2006 Feb; 43(2 Suppl 1):S207-20. PubMed ID: 16447262
[TBL] [Abstract][Full Text] [Related]
19. [Combination therapy for chronic viral hepatitis C].
Zeuzem S
Dtsch Med Wochenschr; 2003 Feb; 128(8):370-4. PubMed ID: 12594622
[No Abstract] [Full Text] [Related]
20. Re-treatment of chronic hepatitis C patients after relapse: efficacy of peginterferon-alpha-2a (40 kDa) and ribavirin.
Berg C; Goncales FL; Bernstein DE; Sette H; Rasenack J; Diago M; Jensen DM; Graham P; Cooksley G
J Viral Hepat; 2006 Jul; 13(7):435-40. PubMed ID: 16792536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
